DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
July 30 2024 - 5:30PM
UK Regulatory
DBV Technologies Announces Filing of 2024 Half-Year Report ―
Conditions for Accessing or Consulting the Report
Châtillon, France, July 30, 2024
DBV Technologies Announces Filing of
2024 Half-Year Report ― Conditions for Accessing or Consulting the
Report
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company focused on treatment options for food
allergies and other immunologic conditions with significant unmet
medical need (the “Company”), today announced the filing, for the
semester ended June 30, 2024, of its Half-Year Report with the
French market authority, “Autorité des Marchés Financiers”
(“AMF”).
The 2024 Half-Year Report can be consulted or
downloaded from the Company’s website (www.dbv-technologies.com) in
the section Investors/Financial Information, and on the AMF website
(www.amf-france.org), in French only.
It is also available free of charge upon
request:
- by mail : DBV Technologies – 107
avenue de la République 92320 Châtillon, France ;
- by email:
investors@dbv-technologies.com.
About DBV
Technologies
DBV Technologies is a clinical-stage biopharmaceutical company
developing treatment options for food allergies and other
immunologic conditions with significant unmet medical need. DBV is
currently focused on investigating the use of its proprietary
technology platform, Viaskin™, to address food allergies, which are
caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies, including
young children. Through epicutaneous immunotherapy (EPIT™), the
Viaskin platform is designed to introduce microgram amounts of a
biologically active compound to the immune system through intact
skin. EPIT is a new class of non-invasive treatment that seeks to
modify an individual’s underlying allergy by re-educating the
immune system to become desensitized to allergen by leveraging the
skin’s immune tolerizing properties. DBV is committed to
transforming the care of food allergic people. The Company’s food
allergy programs include ongoing clinical trials of Viaskin Peanut
in peanut allergic toddlers (1 through 3 years of age) and children
(4 through 7 years of age).
DBV Technologies is headquartered in Châtillon,
France, with North American operations in Warren, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing one ordinary share) are traded on the Nasdaq Stock
Market (Ticker: DBVT).
For more information, please visit www.dbv-technologies.com and
engage with us on X (formerly Twitter) and LinkedIn.
Viaskin and EPIT are trademarks of DBV
Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com
DBV Technologies (TG:DBV)
Historical Stock Chart
From Oct 2024 to Nov 2024
DBV Technologies (TG:DBV)
Historical Stock Chart
From Nov 2023 to Nov 2024
